Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

golfyeti

Rank: Vice President [?]

Points: 24483 [?]

Votes: 217 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

ImmunoSupremo

posted on Dec 22, 2020 10:00AM

Great points! Some I wasn't aware of.

"Not sure of the compounds that are used to make apabetalone.. but..."

Which compounds shouldn't matter since we have years of usage and outstanding safety data already confirmed.

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply